Absci Q1 Revenue Falls 83% to $0.2M as ABS-201 Trial Progresses
Absci dosed four SAD cohorts in its Phase 1/2a HEADLINE trial for ABS-201, with safety and PK data supporting two-to-three injections over six months and MAD dosing in alopecia patients. The company added anti-PRLR ABS-202 to its pipeline and saw Q1 revenue drop to $0.2 million from $1.2 million.
1. ABS-201 Trial Progress
Absci dosed all four planned single ascending dose cohorts in its Phase 1/2a HEADLINE trial for ABS-201, reporting favorable safety data. Preliminary pharmacokinetic modeling supports a two-to-three injection dosing interval over six months, and the company has initiated multiple ascending dose dosing in androgenetic alopecia participants.
2. Addition of ABS-202 to Pipeline
The company expanded its prolactin receptor program by adding ABS-202, a second anti-PRLR antibody now in preclinical development for an undisclosed inflammation and immunology indication, strengthening its generative AI-designed therapeutic portfolio.
3. Endometriosis Advisory Board
Absci launched a clinical advisory board for its ABS-201 endometriosis program, enlisting experts from top medical institutions to guide potential Phase 2 trial design and strategy in late 2026, aiming to address a significant unmet medical need.
4. Q1 2026 Financial Results
For the quarter ended March 31, 2026, Absci reported revenue of $0.2 million, down from $1.2 million a year earlier, reflecting changes in partner contributions and sustained investment in research and development.